Skip to main content
Fig. 5 | Journal of Biomedical Science

Fig. 5

From: Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models

Fig. 5

Plasma soluble urokinase-type plasminogen activator (uPA) receptor (suPAR) levels and expression patterns in a focal segmental glomerulosclerosis (FSGS) mouse model. a Plasma suPAR levels were determined in the wild-type (WT) and uPA−/− groups during the course of the experiment until 4 weeks after Adriamycin treatment. b Immunoblot analysis of the expression of plasma suPAR variants in the WT (upper panel) and uPA−/− (lower panel) groups at the indicated time points are presented. # p < 0.05 vs. week 0 (W0); *p < 0.05 vs. the WT

Back to article page